Business Wire

MED™ 3D Printed Pharmaceutical Product Receives IND Clearance From the US FDA

Share

Triastek, Inc. (“Triastek”), a pharmaceutical company specializing in 3D printing of drug products, announced today that the United States Food and Drug Administration (FDA) has approved its Investigational New Drug (IND) 505(b)(2) application for its first 3D printed drug product – T19, indicated for the treatment of rheumatoid arthritis (RA).Developed in-house, Triastek has global intellectual property rights to the T19 3D printed formulation.

The novel design made possible by 3D printing allows T19 to function as a chronotherapeutic drug delivery system, targeting the circadian nature of RA symptoms. Patients take T19 at bedtime with the tablet releasing drug in a delayed manner such that the blood concentration peaks in the early morning hours when the symptoms of pain, joint stiffness and dysfunction are most acute. T19 utilizes Melt Extrusion Deposition (MEDTM) 3D printing technology to achieve three-dimensional tablet structures that allow precise control of drug release to achieve the desired target PK in the human body, with the goal of addressing these unmet needs of RA patients.

It is predicted that by 2025, the global RA market will reach $30.7 billion (CAGR 4.5%), with T19's unique chronotherapeutic delivery system providing patients with a much-needed therapeutic option. Informa, a pharmaceutical market intelligence consulting company, suggests that T19 can capture substantial portion of RA market in China and the U.S after launch.

Triastek plans to apply for IND approval in China later this year, followed by applications in Japan and Europe. The New Drug Application (NDA) of T19 is expected to be filed to the U.S. FDA in 2023.

Following T19, Triastek has developed 505(b)(2) product portfolio to meet specific clinical needs and improve the outcomes of drug therapy using MEDTM 3D printing technology.

Background on MEDTM 3D printing technology

The MEDTM 3D printing technology platform encompasses digital pharmaceutical dosage form design, an efficient product development approach and automated intelligent manufacturing. Tablets can be constructed to have sophisticated shapes and internal geometric structures that serve to modulate the onset time, kinetics, duration, and mode of drug release with great predictability and reproducibility. This customizable release kinetics can help to enhance therapeutic effects, lower side effects, improve compliance, and efficiently develop pharmaceutical products in different stages.

Triastek has also developed a novel pharmaceutical product development method, 3D printing formulation by design (3DFbD®), to circumvent the trial and error or experience oriented traditional formulation development process. This methodology greatly improves the efficiency and success rate of drug product development, thereby reducing development time and costs. Moreover, integration of real-time Process Analytical Technology (PAT) in the continuous MEDTM 3D printing manufacturing system enables continuous monitoring of the manufacturing process to assure production quality, reduce manufacturing cost, and to provide convenience for regulatory monitoring.

In April 2020, Triastek’s MEDTM 3D printing was accepted into the FDA Emerging Technology Program (ETP). FDA recognized MEDTM 3D printing based on the following features: (a) the proposed use of a MEDTM based 3D technology to manufacture modified release solid oral dosage form, and (b) a fully automated process using PAT and feedback controls.

Dr. Senping Cheng, co-founder and CEO of Triastek, said, “Triastek is committed to improving the efficiency of formulation development, enhancing the effects of drug products, and ensuring the quality of drug delivered to patients by using 3D printing technology platform. The FDA IND clearance of T19 is an important milestone in the development and application of MEDTM 3D printing technology.”

Dr. Xiaoling Li, co-founder and CSO of Triastek, said, “We believe that the MEDTM 3D printing technology will be the enabler for digital pharmaceutical product development and intelligent drug manufacturing. Triastek will work with any interested parties to take advantage of this platform technology for developing pharmaceutical products with better clinical value and higher product quality.”

About Triastek, Inc.

Triastek is an international pharmaceutical company founded in July 2015 by Dr. Senping Cheng, who has entrepreneurial experience both in China and the United States, and Dr. Xiaoling Li, an American pharmaceutical scientist and educator. It is committed to building a novel 3D printing pharmaceutical technology platform for dosage form design, product development, and intelligent manufacturing. In-house product development and co-development with partners are two main business models; in terms of co-development, Triastek has reached a number of agreements with top multinational and Chinese pharmaceutical companies. Triastek’s mission is to be a global leader in the field of 3D printing pharmaceuticals and establish a new era of intelligent pharmaceutical manufacturing.

For more information, please visit Triastek’s website at https://www.triastek.com/indexen.html

Contact information

Business Development and Public Relations:
Eric Tsai
Business Development Director
etsai@triastek.com
M: +86 18502118450

Investor Relations:
Limin Zhang
Executive Assistant to CEO
lzhang@triastek.com
M: +86 13851775094

About Business Wire

Business Wire
Business Wire
24 Martin Lane
EC4R 0DR London

+44 20 7626 1982http://www.businesswire.co.uk

(c) 2018 Business Wire, Inc., All rights reserved.

Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Coty Lands Industry First With Sustainability Certificate for Lancaster Sun Care Products21.4.2021 10:00:00 CEST | Press release

Coty Inc. (NYSE: COTY), one of the world’s leading beauty companies and the global leader in fragrances, today announced that Lancaster has become the first ever sun care brand awarded the prestigious C2C CertifiedMaterial Health Certificate at the Silver level from the Cradle to Cradle Products Innovation Institute. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210421005237/en/ (Photo: Business Wire) The award indicates that 100% of the ingredients in Lancaster Sun Sensitive collection –Lancaster’s first clean and vegan range, and its most environmentally friendly yet - meet the Institute’s strict criteria. In addition to recognizing the sustainable innovation behind the collection, the Certification serves as the foundation for further improving the sustainability and product safety of sun care products over time. Lancaster Sun Sensitive collection provides broad sun protection* targeting 100% of sun spectrum through a cl

The Climate Pledge Announces More Than 100 Signatories Committed to Achieving Net-Zero Carbon by 2040 or Sooner21.4.2021 09:01:00 CEST | Press release

Today, Amazon and Global Optimism announced that more than 100 companies have now signed The Climate Pledge. Among the 52 new signatories joining The Climate Pledge today are well-known brands including Alaska Airlines, Colgate-Palmolive, HEINEKEN, PepsiCo, Telefónica, and Visa. Pledge signatories in total generate more than $1.4 trillion in global annual sales and have more than 5 million employees across 25 industries in 16 countries—demonstrating the collective impact The Climate Pledge can have in addressing climate change. Signatories to The Climate Pledge agree to: Measure and report greenhouse gas emissions on a regular basis. Implement decarbonization strategies in line with the Paris Agreement through real business changes and innovations, including efficiency improvements, renewable energy, materials reductions, and other carbon emission elimination strategies. Neutralize any remaining emissions with additional, quantifiable, real, permanent, and socially beneficial offsets t

Shippeo Sustains Stellar Growth, Recognized in 2021 Gartner Magic Quadrant for Real-time Transportation Visibility Platforms21.4.2021 09:00:00 CEST | Press release

Shippeo, the European leader in real-time supply chain transportation visibility, has been recognized in the Gartner Magic Quadrant for Real-time Transportation Visibility Platforms 2021. The complimentary report is available at shippeo.com. Shippeo COO Lucien Besse is pleased to see the company’s market momentum being acknowledged. “We believe our recognition in the Magic Quadrant reflects upon our heavy investment in R&D and rapid deployment support over the past year as the pandemic stimulates unprecedented interest in RTTV solutions.” This interest has led Gartner to predict that, “by 2023, 50% of global product-centric enterprises will have invested in real-time transportation visibility platforms.” “We’re proud to have a market-leading visibility product and to have achieved strong growth with some of the highest customer recommendation rates,” adds Besse. The company has also developed the most accurate and reliable ETA in the industry while offering full GDPR compliance. The CO

Biometrics Experts and New Study Highlight How Behavioral Biometrics Supports Strict Regulation and Offers Better Data Privacy Protections21.4.2021 09:00:00 CEST | Press release

BehavioSec, the industry pioneer and technology leader for behavioral biometrics and continuous authentication, today announced new findings that organizations and consumers can feel more comfortable with wider use of behavioral biometrics to safeguard their online digital experiences and identities. Following a year of digital transformation on a societal level, the demand for better online user experience and a stronger level of digital identity protection has become essential. With a year when the world has seen a combination of personal data theft with new rulings and proposed legislation, like the EU Schrems II in July 2020 and the US National Biometrics Information Privacy Act in August [US Senators Merkley, D-OR and Sanders, I-VT], the need for expert guidance has never been higher. BehavioSec shares this research and a company milestone to highlight how behavioral biometrics can be adopted transparently with clear benefits, and in compliant fashion with comprehensive data prote

GE og Hitachi ABB Power Grids signerer en banebrytende avtale for å redusere miljøpåvirkning i elektrisitetsforsyningen.21.4.2021 09:00:00 CEST | Pressemelding

GE Renewable Energy's Grid Solutions business (NYSE: GE) og Hitachi ABB Power Grids Ltd. kunngjorde i dag en ikke-eksklusiv krysslisensieringsavtale knyttet til bruken av en alternativ gass til svovelheksafluorid (SF6) brukt i høyspenningsutstyr. Denne fluornitrilbaserte gassblandingen har en betydelig redusert innvirkning på miljøet sammenlignet med SF6. I henhold til denne banebrytende avtalen mellom to globale ledere innen kraftteknologi, som ble kunngjort like før Earth Day 2021, vil begge selskapene dele komplementære immaterielle eiendeler relatert til deres respektive SF6-frie løsninger. Dette vil bidra til å akselerere bruken av fluoronitrilbasert miljøeffektiv isolasjons- og koblinggass i høyspentutstyr som et alternativ til SF6. En nylig rapport fra EU-kommisjonen konkluderte med at fluorinitrilbaserte gassblandinger kan være det eneste islolasjons- og koblingsgassalternativet til SF6 når plass er en begrensning. Dagens historiske avtale baner vei for en standard SF6-fri løsn

SES Joins United Nations Global Compact Initiative, Accelerates Purpose-led ESG Programme in 202121.4.2021 08:50:00 CEST | Press release

SES today announced it has joined the United Nations Global Compact, the world’s largest corporate sustainability initiative, underscoring the company's purpose-led Environmental, Social and Governance (ESG) programme. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210420006272/en/ SES Joins United Nations Global Compact Initiative, Accelerates Purpose-led ESG Programme in 2021 (Photo: Business Wire) By committing to the UN Global Compact framework, SES is now firmly aligning its long-standing societal and environmental impact efforts to the company’s purpose – doing the extraordinary in space to deliver amazing experiences everywhere on earth – and delivering on its ambitions to provide cloud-enabled, satellite-based intelligent connectivity and to make a difference worldwide. The UN Global Compact is a corporate initiative that encourages both business and non-business organisations to establish and define strategies, poli

Australia Flexes Muscle in Talent War with Newest Immigration Program21.4.2021 07:30:00 CEST | Press release

The global battle for talent supercharged by the Covid-19 pandemic shows no signs of abating, with Australia sending out strong signals that it intends to succeed with its latest immigration offering under the Australia Global Business and Talent Attraction Taskforce. Under the purview of the taskforce, there is a fast-tracked visa program with a streamlined path to permanent residence for talented individuals. The Global Talent visa has been designed to grow Australia’s innovation and tech economies in a bid to boost economic recovery, enhance resilience, and drive competitiveness by attracting dynamic, highly skilled individuals to relocate to its safe shores. With no age limit or investment prerequisite, the only requirements for applicants are to be internationally recognized, prominent in their field, and able to provide evidence of outstanding achievements. The 10 future-focused target sectors are: Agri-food and AgTech, Energy, Health Industries, Defence, Advanced Manufacturing a